Year Book of Oncology 2013

1. Cover image - p. 1 2. Title page - p. 2 3. Table of Contents - p. 3 4. Chapter 1. CANCER BIOLOGY - p. 8 5. Earlier Age of Onset of BRCA Mutation-Related Cancers in Subsequent Generations - p. 9 6. Punctuated Evolution of Prostate Cancer Genomes - p. 10 7. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy - p. 11 8. Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia - p. 12 9. Development of a Prognostic Model for Breast Cancer Survival in an Open Challenge Environment - p. 13 10. Chapter 2. CANCER PREVENTION - p. 14 11. Multivitamins in the prevention of cancer in men: the Physicians' Health Study II randomized controlled trial - p. 15 12. Chapter 3. CANCER THERAPIES - p. 16 13. Statin use and reduced cancer-related mortality - p. 17 14. Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy - p. 18 15. Chapter 4. CHEMOTHERAPY:MECHANISMS AND SIDE EFFECTS - p. 19 16. Patients' Expectations about Effects of Chemotherapy for Advanced Cancer - p. 20 17. Chapter 5. BREAST CANCER - p. 21 18. General Issues in Breast cancer - p. 22 19. Assessing the Impact of a Cooperative Group Trial on Breast Cancer Care in the Medicare Population - p. 23 20. Association Between Age at Diagnosis and Disease-Specific Mortality Among Postmenopausal Women With Hormone Receptor–Positive Breast Cancer - p. 24 21. Pain Outcomes in Patients With Advanced Breast Cancer and Bone Metastases: Results From a Randomized, Double-Blind Study of Denosumab and Zoledronic Acid - p. 25 22. Active Smoking and Breast Cancer Risk: Original Cohort Data and Meta-Analysis - p. 26 23. Effect of Three Decades of Screening Mammography on Breast-Cancer Incidence - p. 27 24. The benefits and harms of breast cancer screening: an independent review - p. 28 25. Prevention - p. 29 26. Effect of three decades of screening mammography on breast-cancer incidence - p. 30 27. Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in the Women's Health Initiative Observational Study - p. 31 28. Early Stage and Adjuvant Therapy - p. 32 29. Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27—A Randomized Controlled Phase III Trial - p. 33 30. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial - p. 34 31. Diagnostic Imaging - p. 35 32. Evaluation of breast amorphous calcifications by a computer-aided detection system in full-field digital mammography - p. 36 33. Locally Advanced Breast Cancer: MR Imaging for Prediction of Response to Neoadjuvant Chemotherapy—Results from ACRIN 6657/I-SPY TRIAL - p. 37 34. Preoperative Breast MRI Can Reduce the Rate of Tumor-Positive Resection Margins and Reoperations in Patients Undergoing Breast-Conserving Surgery - p. 39 35. Computer-aided Detection of Masses at Mammography: Interactive Decision Support Versus Prompts - p. 43 36. Breast Cancer: Assessing Response to Neoadjuvant Chemotherapy by Using US-guided Near-Infrared Tomography - p. 44 37. Sentinel Node Biopsy - p. 46 38. High risk of non-sentinel node metastases in a group of breast cancer patients with micrometastases in the sentinel node - p. 47 39. Surgical Treatment - p. 50 40. An Updated Meta-Analysis on the Effectiveness of Preoperative Prophylactic Antibiotics in Patients Undergoing Breast Surgical Procedures - p. 51 41. Axillary Dissection Versus No Axillary Dissection in Older Patients With T1N0 Breast Cancer: 15-Year Results of a Randomized Controlled Trial - p. 52 42. Reduced Incidence of Breast Cancer–Related Lymphedema following Mastectomy and Breast Reconstruction versus Mastectomy Alone - p. 53 43. Tumor Biology - p. 54 44. Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression - p. 55 45. CHEK2*1100delC Heterozygosity in Women With Breast Cancer Associated With Early Death, Breast Cancer–Specific Death, and Increased Risk of a Second Breast Cancer - p. 56 46. Breast Conserving Therapy - p. 58 47. Variability in Reexcision Following Breast Conservation Surgery - p. 59 48. Hormonal Therapy - p. 60 49. Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer - p. 61 50. Follow-up Care - p. 63 51. A Prospective Surveillance Model for Physical Rehabilitation of Women With Breast Cancer: Chemotherapy-Induced Peripheral Neuropathy - p. 64 52. Efficacy of Cognitive Behavioral Therapy and Physical Exercise in Alleviating Treatment-Induced Menopausal Symptoms in Patients With Breast Cancer: Results of a Randomized, Controlled, Multicenter Trial - p. 65 53. Prognostic Factors - p. 66 54. Prognostic Impact of Pregnancy After Breast Cancer According to Estrogen Receptor Status: A Multicenter Retrospective Study - p. 67 55. Economic, Legal, and Social Issues - p. 68 56. Cost Effectiveness of Fracture Prevention in Postmenopausal Women Who Receive Aromatase Inhibitors for Early Breast Cancer - p. 69 57. Chapter 6. GENITOURINARY - p. 71 58. Bladder - p. 72 59. Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer - p. 73 60. Prostate - p. 74 61. Diagnostic Performance of PCA3 to Detect Prostate Cancer in Men with Increased Prostate Specific Antigen: A Prospective Study of 1,962 Cases - p. 75 62. Cost-effectiveness analysis of SBRT versus IMRT: an emerging initial radiation treatment option for organ-confined prostate cancer - p. 76 63. Radical Prostatectomy in Austria From 1992 to 2009: An Updated Nationwide Analysis of 33,580 Cases - p. 77 64. Interval to Biochemical Failure as a Biomarker for Cause-Specific and Overall Survival After Dose-Escalated External Beam Radiation Therapy for Prostate Cancer - p. 78 65. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial - p. 79 66. Management of Older Men With Clinically Localized Prostate Cancer: The Significance of Advanced Age and Comorbidity - p. 80 67. Quality-of-Life Effects of Prostate-Specific Antigen Screening - p. 81 68. Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy - p. 82 69. Radical Prostatectomy versus Observation for Localized Prostate Cancer - p. 83 70. Variation in Use of Androgen Suppression With External-Beam Radiotherapy for Nonmetastatic Prostate Cancer - p. 84 71. Long-Term Results of an RTOG Phase II Trial (00-19) of External-Beam Radiation Therapy Combined With Permanent Source Brachytherapy for Intermediate-Risk Clinically Localized Adenocarcinoma of the Prostate - p. 85 72. Intensity-Modulated Radiation Therapy, Proton Therapy, or Conformal Radiation Therapy and Morbidity and Disease Control in Localized Prostate Cancer - p. 86 73. Germline Mutations in HOXB13 and Prostate-Cancer Risk - p. 87 74. Prostate-Cancer Mortality at 11 Years of Follow-up - p. 88 75. Racial Differences in Bone Mineral Density and Fractures in Men Receiving Androgen Deprivation Therapy for Prostate Cancer - p. 89 76. Long-term quality of life outcome after proton beam monotherapy for localized prostate cancer - p. 90 77. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer - p. 91 78. Adverse Effects of Robotic-Assisted Laparoscopic Versus Open Retropubic Radical Prostatectomy Among a Nationwide Random Sample of Medicare-Age Men - p. 92 79. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy - p. 93 80. Chapter 7. GYNECOLOGY - p. 94 81. Cervix - p. 95 82. ACR Appropriateness Criteria® Pretreatment Planning of Invasive Cancer of the Cervix - p. 96 83. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group - p. 97 84. Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study - p. 98 85. A systematic review of randomized trials assessing human papillomavirus testing in cervical cancer screening - p. 99 86. Chemotherapy for advanced and recurrent cervical carcinoma: Results from cooperative group trials - p. 100 87. Endometrial - p. 101 88. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study - p. 102 89. Did GOG99 and PORTEC1 change clinical practice in the United States? - p. 103 90. Adjuvant Radiotherapy for Stage I Endometrial Cancer: An Updated Cochrane Systematic Review and Meta-analysis - p. 104 91. Adjuvant Therapy for High-Grade, Uterus-Limited Leiomyosarcoma: Results of a Phase 2 Trial (SARC 005) - p. 105 92. Recurrence and Survival After Random Assignment to Laparoscopy Versus Laparotomy for Comprehensive Surgical Staging of Uterine Cancer: Gynecologic Oncology Group LAP2 Study - p. 106 93. Ovarian - p. 107 94. Long-Term Ovarian Cancer Survival Associated With Mutation in BRCA1 or BRCA2 - p. 108 95. Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: A Gynecologic Oncology Group Study - p. 109 96. Results of Annual Screening in Phase I of the United Kingdom Familial Ovarian Cancer Screening Study Highlight the Need for Strict Adherence to Screening Schedule - p. 110 97. Randomized, Open-Label, Phase III Study Comparing Patupilone (EPO906) With Pegylated Liposomal Doxorubicin in Platinum-Refractory or -Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian Tube, or Primary Peritoneal Cancer - p. 111 98. Abagovomab As Maintenance Therapy in Patients With Epithelial Ovarian Cancer: A Phase III Trial of the AGO OVAR, COGI, GINECO, and GEICO—The MIMOSA Study - p. 112 99. A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy - p. 113 100. Declining Second Primary Ovarian Cancer After First Primary Breast Cancer - p. 114 101. Chapter 8. GASTROINTESTINAL - p. 115 102. Colon: Advanced - p. 116 103. Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer: A Randomized Trial - p. 117 104. Colorectal Cancer - p. 118 105. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04 - p. 119 106. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years - p. 120 107. Colorectal-Cancer Incidence and Mortality with Screening Flexible Sigmoidoscopy - p. 121 108. Colonoscopic Polypectomy and Long-Term Prevention of Colorectal-Cancer Deaths - p. 122 109. Association of KRAS G13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab - p. 123 110. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial - p. 124 111. Estrogen Plus Progestin and Colorectal Cancer Incidence and Mortality - p. 125 112. Aspirin Use, Tumor PIK3CA Mutation, and Colorectal-Cancer Survival - p. 126 113. Pancreas - p. 127 114. Open-Label, Multicenter, Randomized Phase III Trial of Adjuvant Chemoradiation Plus Interferon Alfa-2b Versus Fluorouracil and Folinic Acid for Patients With Resected Pancreatic Adenocarcinoma - p. 128 115. Carbohydrate Antigen 19-9 is a Prognostic and Predictive Biomarker in Patients With Advanced Pancreatic Cancer Who Receive Gemcitabine-Containing Chemotherapy: A Pooled Analysis of 6 Prospective Trials - p. 129 116. EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104 - p. 130 117. Re-resection for Isolated Local Recurrence of Pancreatic Cancer is Feasible, Safe, and Associated with Encouraging Survival - p. 131 118. Miscellaneous - p. 132 119. Long-Term Update of US GI Intergroup RTOG 98-11 Phase III Trial for Anal Carcinoma: Survival, Relapse, and Colostomy Failure With Concurrent Chemoradiation Involving Fluorouracil/Mitomycin Versus Fluorouracil/Cisplatin - p. 133 120. Chapter 9. HEMATOLOGIC MALIGNANCIES - p. 134 121. Leukemia and Myelodysplastic Syndrome - p. 135 122. Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG) - p. 136 123. Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia - p. 137 124. DNA methylation changes are a late event in acute promyelocytic leukemia and coincide with loss of transcription factor binding - p. 138 125. Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia - p. 139 126. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia - p. 140 127. inv(16)/t(16;16) acute myeloid leukemia with non–type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations - p. 141 128. Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia - p. 142 129. Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia - p. 143 130. The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML - p. 144 131. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia - p. 145 132. Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway - p. 146 133. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia - p. 147 134. Chapter 10. THORACIC CANCER - p. 148 135. Biology - p. 149 136. Lung Cancer That Harbors a HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives - p. 150 137. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis - p. 151 138. Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions - p. 152 139. Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers - p. 153 140. Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors - p. 154 141. Fibroblast Growth Factor Receptor 1 Gene Amplification Is Associated With Poor Survival and Cigarette Smoking Dosage in Patients With Resected Squamous Cell Lung Cancer - p. 155 142. First-Line Metastatic Non-Small-Cell Lung Cancer - p. 156 143. Randomized Phase II Study of Ixabepilone or Paclitaxel Plus Carboplatin in Patients With Non–Small-Cell Lung Cancer Prospectively Stratified by Beta-3 Tubulin Status - p. 157 144. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial - p. 158 145. Second-Line Metastatic Non-Small-Cell Lung Cancer - p. 159 146. Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer - p. 160 147. Aflibercept and Docetaxel Versus Docetaxel Alone After Platinum Failure in Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer: A Randomized, Controlled Phase III Trial - p. 161 148. Pemetrexed Versus Pemetrexed and Carboplatin As Second-Line Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the GOIRC 02-2006 Randomized Phase II Study and Pooled Analysis With the NVALT7 Trial - p. 162 149. Non-Small-Cell: Early Stage and Adjuvant Therapy - p. 163 150. Incorporating Bevacizumab and Erlotinib in the Combined-Modality Treatment of Stage III Non–Small-Cell Lung Cancer: Results of a Phase I/II Trial - p. 164 151. Advanced Diseases - p. 165 152. Phase II Trial of Erlotinib Plus Concurrent Whole-Brain Radiation Therapy for Patients With Brain Metastases From Non–Small-Cell Lung Cancer - p. 166 153. Chapter 11. HEAD AND NECK - p. 167 154. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomized phase 3 trial - p. 168 155. Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial - p. 169 156. Deintensification Candidate Subgroups in Human Papillomavirus–Related Oropharyngeal Cancer According to Minimal Risk of Distant Metastasis - p. 170 157. Induction Chemotherapy Followed by Either Chemoradiotherapy or Bioradiotherapy for Larynx Preservation: the TREMPLIN Randomized Phase II Study - p. 171 158. Long-Term Results of RTOG 91-11: A Comparison of Three Nonsurgical Treatment Strategies to Preserve the Larynx in Patients With Locally Advanced Larynx Cancer - p. 172 159. Randomized Phase III Trial of Induction Chemotherapy With Docetaxel, Cisplatin, and Fluorouracil Followed by Surgery Versus Up-Front Surgery in Locally Advanced Resectable Oral Squamous Cell Carcinoma - p. 173 160. Cisplatin and Radiotherapy With or Without Erlotinib in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Phase II Trial - p. 174 161. Associations among speech, eating, and body image concerns for surgical patients with head and neck cancer - p. 175 162. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial - p. 176 163. A systematic review of head and neck cancer quality of life assessment instruments - p. 177 164. Evaluation of Human Papillomavirus Antibodies and Risk of Subsequent Head and Neck Cancer - p. 178 165. Management of Human Papillomavirus–Positive and Human Papillomavirus–Negative Head and Neck Cancer - p. 179 166. Chapter 12. PEDIATRIC CANCER - p. 180 167. Hematologic Disorders - p. 181 168. Association Between Radiotherapy vs No Radiotherapy Based on Early Response to VAMP Chemotherapy and Survival Among Children With Favorable-Risk Hodgkin Lymphoma - p. 182 169. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis - p. 183 170. Leukemia - p. 184 171. The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study - p. 185 172. Nonadherence to Oral Mercaptopurine and Risk of Relapse in Hispanic and Non-Hispanic White Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group - p. 186 173. Second Malignant Neoplasms After Treatment of Childhood Acute Lymphoblastic Leukemia - p. 187 174. Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia - p. 188 175. Clonal selection in xenografted TAM recapitulates the evolutionary process of myeloid leukemia in Down syndrome - p. 189 176. Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia: Results of the CA180-018 Phase I Dose-Escalation Study of the Innovative Therapies for Children With Cancer Consortium - p. 190 177. Development and validation of a single-cell network profiling assay-based classifier to predict response to induction therapy in paediatric patients with de novo acute myeloid leukaemia: a report from the Children's Oncology Group - p. 191 178. Randomized trial comparing liposomal daunorubicin with idarubicin in induction for pediatric acute myeloid leukemia – Results from Study AMLBFM 2004 - p. 192 179. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial - p. 193 180. Neuro-Oncology - p. 194 181. High Frequency of Germline SUFU Mutations in Children With Desmoplastic/Nodular Medulloblastoma Younger Than 3 Years of Age - p. 195 182. Solid Tumors - p. 196 183. G-CSF Receptor Positive Neuroblastoma Subpopulations Are Enriched in Chemotherapy-Resistant or Relapsed Tumors and Are Highly Tumorigenic - p. 197 184. Outcome After Surgery Alone or With Restricted Use of Chemotherapy for Patients With Low-Risk Neuroblastoma: Results of Children's Oncology Group Study P9641 - p. 198 185. The Use of Computed Tomography in Pediatrics and the Associated Radiation Exposure and Estimated Cancer Risk - p. 199 186. Miscellaneous - p. 200 187. High Risk of Symptomatic Cardiac Events in Childhood Cancer Survivors - p. 201 188. Chapter 13. SARCOMA - p. 202 189. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial - p. 203 190. Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy - p. 204 191. Chapter 14. SUPPORTIVE CARE - p. 205 192. A combined pain consultation and pain education program decreases average and current pain and decreases interference in daily life by pain in oncology outpatients: A randomized controlled trial - p. 206 193. Cytokine use and survival in the first-line treatment of ovarian cancer: A Gynecologic Oncology Group Study - p. 207 194. Chapter 15. MISCELLANEOUS - p. 208 195. Suicide and Cardiovascular Death after a Cancer Diagnosis - p. 209